Antisense oligonucleotides: modifications and clinical trials

There has been an upsurge in the number of clinical trials involving chemically modified oligonucleotide-based drug candidates after the FDA approval of Vitravene, Macugen, and recently, Kynamro. Over the years, different types of backbone, nucleobase and/or sugar-modified oligonucleotides have been synthesized because natural DNA/RNA based oligonucleotides pose some limitations, such as poor binding affinity, low degree of nuclease resistance, affecting their direct use in antisense therapeutics. In this review article, we discuss in detail different modifications of nucleosides/oligonucleotides along with the related clinical trials, which demonstrated their potential as drug candidates for antisense and related nucleic acid based therapeutics.

[1]  A. Prasad,et al.  Nucleic acid therapeutics: basic concepts and recent developments , 2014 .

[2]  R. Kumar,et al.  Modified Oligonucleotides: Strides Towards Antisense Drugs , 2013 .

[3]  T. P. Prakash,et al.  Synthesis and biophysical properties of constrained D-altritol nucleic acids (cANA). , 2013, Organic letters.

[4]  A. Banerjee,et al.  C3'-endo-puckered pyrrolidine containing PNA has favorable geometry for RNA binding: novel ethano locked PNA (ethano-PNA). , 2013, Bioorganic & medicinal chemistry.

[5]  J. Watts.  Locked nucleic acid: tighter is different. , 2013, Chemical communications.

[6]  Wei Zhang,et al.  Effects of miR-155 antisense oligonucleotide on breast carcinoma cell line MDA-MB-157 and implanted tumors. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[7]  Veysi Oner,et al.  Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model. , 2013, International journal of ophthalmology.

[8]  K. McKeage,et al.  Mipomersen Sodium: First Global Approval , 2013, Drugs.

[9]  N. La Monica,et al.  Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist. , 2013, Journal of hepatology.

[10]  E. Stroes,et al.  Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises. , 2013, The Netherlands journal of medicine.

[11]  J. Shay,et al.  Imetelstat (a telomerase antagonist) exerts off-target effects on the cytoskeleton , 2013, International journal of oncology.

[12]  Yukio Ando,et al.  Guideline of transthyretin-related hereditary amyloidosis for clinicians , 2013, Orphanet Journal of Rare Diseases.

[13]  P. Iversen,et al.  Development of Novel Bioanalytical Methods to Determine the Effective Concentrations of Phosphorodiamidate Morpholino Oligomers in Tissues and Cells , 2013, BioResearch open access.

[14]  C. Olsen,et al.  Design and Synthesis of LNA-Based Mercaptoacetamido-Linked Nucleoside Dimers , 2013, Nucleosides, nucleotides & nucleic acids.

[15]  R. Schachar,et al.  Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). , 2012, Investigative ophthalmology & visual science.

[16]  A. Levin,et al.  Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey. , 2012, Toxicology.

[17]  J. Tardif,et al.  Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy , 2012, PloS one.

[18]  S. Henry,et al.  Pharmacodynamics and Subchronic Toxicity in Mice and Monkeys of ISIS 388626, a Second-Generation Antisense Oligonucleotide That Targets Human Sodium Glucose Cotransporter 2 , 2012, Journal of Pharmacology and Experimental Therapeutics.

[19]  P. Iversen,et al.  Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections , 2012, Viruses.

[20]  S. Kauppinen,et al.  Discovering the first microRNA-targeted drug , 2012, The Journal of cell biology.

[21]  Piero Carninci,et al.  Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat , 2012, Nature.

[22]  A. Jazayeri,et al.  Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals , 2012, Molecular therapy. Nucleic acids.

[23]  H. Ortega,et al.  Novel targeted therapies for eosinophilic disorders. , 2012, The Journal of allergy and clinical immunology.

[24]  G. Borthakur,et al.  Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia , 2012 .

[25]  Z. Deng,et al.  Phosphorothioate DNA as an antioxidant in bacteria , 2012, Nucleic acids research.

[26]  S. Obika,et al.  Hybridizing ability and nuclease resistance profile of backbone modified cationic phosphorothioate oligonucleotides. , 2012, Bioorganic & medicinal chemistry.

[27]  B. Jilma,et al.  The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease , 2012, Thrombosis and Haemostasis.

[28]  J. Mendell,et al.  Emerging drugs for Duchenne muscular dystrophy , 2012, Expert opinion on emerging drugs.

[29]  R. Pandey,et al.  Metabolism, Pharmacokinetics, Tissue Distribution, and Stability Studies of the Prodrug Analog of an Anti-Hepatitis B Virus Dinucleoside Phosphorothioate , 2012, Drug Metabolism and Disposition.

[30]  Z. Estrov,et al.  Targeting Signal Transducer and Activator of Transcription (STAT) for Anticancer Therapy , 2012 .

[31]  J. Sheppard,et al.  Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[32]  M. Gleave,et al.  Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  J. Burnett,et al.  RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.

[34]  J. Dipersio,et al.  Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia , 2012, Cancer.

[35]  K. Schlingensiepen,et al.  The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2. , 2011, Current pharmaceutical biotechnology.

[36]  D. Brennan,et al.  Delayed Graft Function in the Kidney Transplant , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  M. Gleave,et al.  OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer , 2011, Cell Death and Disease.

[38]  C. Burrows,et al.  Chemical modification of siRNA bases to probe and enhance RNA interference. , 2011, The Journal of organic chemistry.

[39]  T. P. Prakash.  An Overview of Sugar‐Modified Oligonucleotides for Antisense Therapeutics , 2011, Chemistry & biodiversity.

[40]  M. Fishman,et al.  A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[41]  L. Klein-Hitpass,et al.  The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia , 2011, Leukemia.

[42]  Bharvin K R Patel,et al.  Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide. , 2011, British journal of clinical pharmacology.

[43]  G. Marcucci,et al.  Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells , 2011, The AAPS Journal.

[44]  T. Kuzel,et al.  Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. , 2010, Journal of the American Academy of Dermatology.

[45]  M. Catley.  Asthma & COPD--IQPC's Second Conference. , 2010, IDrugs : the investigational drugs journal.

[46]  P. Kaiser,et al.  RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. , 2010, American journal of ophthalmology.

[47]  Allen R. Chen,et al.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  Anthony D. Keefe,et al.  Aptamers as therapeutics , 2010, Nature Reviews Drug Discovery.

[49]  D. Corey,et al.  Clinical status of duplex RNA. , 2010, Bioorganic & medicinal chemistry letters.

[50]  H. Ozaki,et al.  Effect of 3'-end capping of aptamer with various 2',4'-bridged nucleotides: Enzymatic post-modification toward a practical use of polyclonal aptamers. , 2010, Bioorganic & medicinal chemistry letters.

[51]  L. Greenberger,et al.  Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide , 2010, Nucleosides, nucleotides & nucleic acids.

[52]  C. Bennett,et al.  RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.

[53]  F. Horn,et al.  GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. , 2009, Ophthalmology.

[54]  P. Fidias,et al.  Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[55]  S. Henry,et al.  Antisense Oligonucleotide Therapy in Diabetic Retinopathy , 2009, Journal of diabetes science and technology.

[56]  L. Singerman.  COMBINATION THERAPY USING THE SMALL INTERFERING RNA BEVASIRANIB , 2009, Retina.

[57]  B. Cosmi.  ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. , 2009, Current opinion in molecular therapeutics.

[58]  Laura Vidal,et al.  Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[59]  S. Leung,et al.  Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer , 2008, Clinical Cancer Research.

[60]  M. Westergaard,et al.  A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth , 2008, Molecular Cancer Therapeutics.

[61]  E. Nakamura,et al.  Triazole-linked analogue of deoxyribonucleic acid ((TL)DNA): design, synthesis, and double-strand formation with natural DNA. , 2008, Organic letters.

[62]  P. Iversen,et al.  c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. , 2008, Lung cancer.

[63]  H. Soreq,et al.  Antisense Treatment for Myasthenia Gravis , 2008, Annals of the New York Academy of Sciences.

[64]  S. Elbashir,et al.  Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). , 2008, Antiviral research.

[65]  R. Amato.  Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. , 2007, Clinical genitourinary cancer.

[66]  S. Agrawal,et al.  Synthetic agonists of Toll-like receptors 7, 8 and 9. , 2007, Biochemical Society transactions.

[67]  C. Cooper,et al.  Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy , 2007, Expert opinion on biological therapy.

[68]  M. Conte,et al.  Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass. , 2007, Cardiovascular drug reviews.

[69]  H. Lyerly,et al.  CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy , 2007, Expert opinion on biological therapy.

[70]  M. Damha,et al.  Oxepane nucleic acids: synthesis, characterization, and properties of oligonucleotides bearing a seven-membered carbohydrate ring. , 2007, Journal of the American Chemical Society.

[71]  K. Gogoi,et al.  Synthesis and RNA binding selectivity of oligonucleotides modified with five-atom thioacetamido nucleic acid backbone structures. , 2007, Organic letters.

[72]  T. P. Prakash,et al.  2'-Modified oligonucleotides for antisense therapeutics. , 2007, Current topics in medicinal chemistry.

[73]  W. Chey,et al.  A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[74]  K. Altmann,et al.  RNA-Binding affinities and crystal structure of oligonucleotides containing five-atom amide-based backbone structures. , 2006, Biochemistry.

[75]  Gang Chen,et al.  Determination of glycosides and sugars in Moutan Cortex by capillary electrophoresis with electrochemical detection. , 2006, Journal of pharmaceutical and biomedical analysis.

[76]  M. Clerici,et al.  Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice. , 2006, Vaccine.

[77]  Y. Lee,et al.  GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors. , 2006, International journal of oncology.

[78]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[79]  P. Iversen,et al.  Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. , 2005, Current opinion in pharmacology.

[80]  T. Aboul-Fadl.  Antisense oligonucleotides: the state of the art. , 2005, Current medicinal chemistry.

[81]  Reena Rao,et al.  Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption , 2005, Nature Medicine.

[82]  Sanjay Goel,et al.  A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers , 2005, Investigational New Drugs.

[83]  D. A. Stein,et al.  Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity. , 2005, Bioconjugate chemistry.

[84]  D. Kohan,et al.  Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[85]  M. Gleave,et al.  Antisense therapy for cancer , 2005, Nature Reviews Cancer.

[86]  W. Guo,et al.  Quantification of raf antisense oligonucleotide (rafAON) in biological matrices by LC-MS/MS to support pharmacokinetics of a liposome-entrapped rafAON formulation. , 2005, Biomedical chromatography : BMC.

[87]  M. Ranson,et al.  Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP , 2005, British Journal of Cancer.

[88]  K. Hillgren,et al.  Development and validation of a sensitive, specific, and rapid hybridization-ELISA assay for determination of concentrations of a ribozyme in biological matrices. , 2004, Journal of pharmaceutical and biomedical analysis.

[89]  L. Paquette.  Spirocyclic Restriction of Nucleosides , 2004 .

[90]  Anton P. McCaffrey,et al.  A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice , 2003, Hepatology.

[91]  J. Wengel,et al.  Synthesis of 2′-Spiro Ribo- and Arabinonucleosides , 2003, Nucleosides, nucleotides & nucleic acids.

[92]  B. Baker,et al.  Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α , 2002, Journal of Pharmacology and Experimental Therapeutics.

[93]  P. Iversen,et al.  Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[94]  Y. Hari,et al.  Synthesis and conformation of 3′,4′-BNA monomers, 3′-O,4′-C-methyleneribonucleosides , 2002 .

[95]  J. Wengel,et al.  Oligodeoxynucleotides containing amide-linked LNA-type dinucleotides: synthesis and high-affinity nucleic acid hybridization. , 2002, Chemical communications.

[96]  C. Lomholt,et al.  A simplified and efficient route to 2'-O, 4'-C-methylene-linked bicyclic ribonucleosides (locked nucleic acid). , 2001, The Journal of organic chemistry.

[97]  J. Micklefield,et al.  Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. , 2001, Current medicinal chemistry.

[98]  C. Rudin,et al.  Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  P. Herdewijn,et al.  CYCLOHEXENE NUCLEIC ACIDS (CeNA) FORM STABLE DUPLEXES WITH RNA AND INDUCE RNASE H ACTIVITY , 2001 .

[100]  S. Crooke.  Potential roles of antisense technology in cancer chemotherapy , 2000, Oncogene.

[101]  P. Herdewijn.  Heterocyclic modifications of oligonucleotides and antisense technology. , 2000, Antisense & nucleic acid drug development.

[102]  Seitz.  Chemically Modified Antisense Oligonucleotides-Recent Improvements of RNA Binding and Ribonuclease H Recruitment. , 1999, Angewandte Chemie.

[103]  K. Miyashita,et al.  Synthesis of a conformationally locked AZT analogue, 3′-azido-3′-deoxy-2′-O,4′-C-methylene-5-methyluridine , 1999 .

[104]  R. Zheng.  Technology evaluation: GEM-92, Hybridon Inc. , 1999, Current opinion in molecular therapeutics.

[105]  C. Leumann,et al.  Synthesis and Thermodynamic and Biophysical Properties of Tricyclo-DNA , 1999 .

[106]  J. Zhang,et al.  Synthesis and hybridization property of an oligonucleotide containing a 3-thioformacetal linked pentathymidylate. , 1999, Bioorganic & medicinal chemistry letters.

[107]  K. Lin,et al.  A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acids. , 1998 .

[108]  D. Coen,et al.  Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922) , 1998, Antimicrobial Agents and Chemotherapy.

[109]  Toshimasa Ishida,et al.  Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3, -endo sugar puckering , 1997 .

[110]  S. Freier,et al.  The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. , 1997, Nucleic acids research.

[111]  E. Swayze,et al.  Synthesis of Novel Nucleic Acid Mimics via the Stereoselective Intermolecular Radical Coupling of 3′‐Iodo Nucleosides and Formaldoximes. , 1997 .

[112]  V. Fritsch,et al.  Amide Backbones with Conformationally Restricted Furanose Rings: Highly Improved Affinity of the Modified Oligonucleotides for Their RNA Complements , 1996 .

[113]  N. Usman,et al.  Synthesis and biological activities of a phosphorodithioate analog of 2',5'-oligoadenylate. , 1995, Nucleic acids research.

[114]  K. Lin,et al.  Tricyclic 2'-Deoxycytidine Analogs: Syntheses and Incorporation into Oligodeoxynucleotides Which Have Enhanced Binding to Complementary RNA , 1995 .

[115]  J. Lebreton,et al.  Synthesis of Oligodeoxyribonucleotides containing dimers with carbamate moieties as replacement of the natural phosphodiester linkage , 1994 .

[116]  P. D. Cook,et al.  Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. , 1993, The Journal of biological chemistry.

[117]  L. C. Bock,et al.  In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. , 1993, Blood.

[118]  A. Matsuda,et al.  Nucleosides and Nucleotides. 108. Synthesis and Optical Properties of Syn-Fixed Carbon-Bridged Pyrimidine Cyclonucleosides , 1992 .

[119]  E. De Clercq,et al.  3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (TSAO) pyrimidine nucleosides. , 1992, Journal of medicinal chemistry.

[120]  M. Egholm,et al.  Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. , 1991, Science.

[121]  E. Uhlmann,et al.  Antisense oligonucleotides: a new therapeutic principle , 1990 .

[122]  A. Lamond,et al.  Highly efficient chemical synthesis of 2'-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. , 1989, Nucleic acids research.

[123]  Wolfram Saenger,et al.  Principles of Nucleic Acid Structure , 1983 .

[124]  K. Jankowski,et al.  Nucleoside conformation is determined by the electronegativity of the sugar substituent. , 1980, Nucleic acids research.

[125]  B. Paterson,et al.  Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[126]  T. Merigan,et al.  Interferon Induction Increased through Chemical Modification of a Synthetic Polyribonucleotide , 1969, Science.

[127]  S. Hirschman,et al.  Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. , 2011, Journal of the American Medical Directors Association.

[128]  C Shad Thaxton,et al.  Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. , 2011, Methods in molecular biology.

[129]  A. Oza,et al.  Phase I Study of MG 98 , an OligonucleotideAntisense Inhibitor of Human DNAMethyltransferase 1 , Given as a 7-Day Infusion in Patients with Advanced SolidTumors , 2009 .

[130]  R. Yu,et al.  A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. , 2006, Journal of hepatology.

[131]  J. Holmlund,et al.  Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. , 2005, Neuro-oncology.

[132]  J. Sloan,et al.  A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[133]  J. Temsamani,et al.  [Antisense oligonucleotides: a new therapeutic approach]. , 1998, Pathologie-biologie.

[134]  F. Eckstein,et al.  Modified oligonucleotides: synthesis and strategy for users. , 1998, Annual review of biochemistry.

[135]  P. Herdewijn,et al.  Hexitol Nucleic Acids (HNA): Synthesis and Properties , 1997 .

[136]  S. Crooke.  Therapeutic Applications of Oligonucleotides , 1992, Bio/Technology.

[137]  M. Stephenson,et al.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.